Skip to content
FIND A HEALTH VALLEY ACTOR

Limula and CSEM partner to automate the production of CAR T cells

CSEM + LIMULA

A Health Valley partnership to revolutionize cancer therapies and to bring a personalised treatment for cancer patients   CSEM supports Lausanne-based start-up Limula in its mission to make cell therapies more affordable. The technology developed enables the automated production of CAR T and other cell therapies at scale. The prototype is now going towards pre-industrial…

Read More

€2M Eurostars funding for a project led by Calciscon

Calciscon

CALCISCON, AMSTERDAM UNIVERSITY MEDICAL CENTERS and ADMESY have signed a collaborative agreement for the development of a laboratory benchtop analyzer for the measurement of the T50 test.   T50 is a unique test for the measurement of calcification propensity in a blood sample. The primary use of T50 is to revolutionize the treatment of patients…

Read More

Xsensio announces an agreement with Mayo Clinic

Xsensio

Xsensio Announces Know-How and Stock Purchase Agreement with Mayo Clinic   Xsensio, a Vaud-Based company that is developing the Lab-on-Skin© sensing platform, announced that it has entered into a know-how and stock purchase agreement with Mayo Clinic for the development of new wearable products based on short term health dynamics in critical care. Xsensio will…

Read More

Comphya raises CHF 850 000 in a convertible loan

CaverSTIM

Comphya SA, developer of the first neuromodulator to treat erectile dysfunction (ED), announced the fundraising of CHF 850k in a convertible loan. This brings the total amount of funds raised to CHF 5.1 Mio.   The financial round included investment from existing shareholders and additional investors. Praxis Spinal Cord Institute, a non-profit organization, also committed…

Read More

FONGIT Innovation Fund

Send your application before 22 July 2026 for the FONGIT Innovation Fund (FIF) FONGIT, Fondation Genevoise pour l’Innovation Technologique, is the first innovation incubator in Switzerland, specialising in technological innovation in Geneva. The organisation currently supports more than 100 startups and projects in the fields of ICT, Engineering, and Life Sciences. It helps innovative projects…

Read More

Research is less profitable for the pharmaceutical industry

Pills ©maksim goncharenok

According to a Deloitte study, investing in research is less and less interesting. The audit and consulting firm used figures from the world’s 20 largest pharmaceutical companies, including the Swiss companies Novartis and Roche.   In 2022, the world’s twenty largest pharmaceutical companies spent 130 billion francs on research and development. This sum has fallen…

Read More

Lonza invested CHF 1 billion in Visp in 2022

Ibex™ Lonza facilit in Visp Switzerland

The biopharmaceutical company employs 5,000 people in Valais, and also announced a 15% sales growth in 2022, representing a total of CHF 6.2 billion   Lonza has invested one billion francs in Visp (VS) and half a billion in Stein (AG) in 2022, according to the chairman of the group’s board of directors, Albert Baehni. Some…

Read More

CHUV, Alithea Genomics and PanGene partner to develop a pan-cancer blood test

Alithea Chuv Pamgene

The three partners secured a €1 million ($1.1 million) in Eurostars grant funding to develop a first of a king pan-cancer blood test to guide immune checkpoint inhibitor (ICI) therapy.   The consortium combines an expertise in clinical research, transcriptomics and kinomic profiling to take a radically new approach to identify a multi-omics biomarker profile…

Read More

BioAlps and the Swiss Health Valley

Magali Bischof Labiotech

Listen to Magali Bischof, BioAlps Secretary General, on Beyond Biotech podcast speaking about the Swiss Health Valley and the role of BioAlps association. Here is the transcription of the interview.   ▶️ Listen to the podcast on Labiotech.eu | From 00:31:50 to 47:30   Could you tell us about BioAlps – when it was formed,…

Read More

CHUV, EPFL, SIB and Roche found molecules able to suppress resistance to immunotherapy

Chuv, Ludwig Institute, EPFL

A breakthrough in the fight against cancer: researchers from EPFL, the Ludwig Institute of the CHUV, the SIB, and Roche have discovered have successfully tested on mice a combined treatment that attacks the most resistant tumors. A test on humans will follow.   Immunotherapy is a cancer treatment that involves reprogramming a patient’s immune system…

Read More